A new triplet therapy for revlimid-refractory multiple myeloma
eMediNexus, 09 November 2018
Based on the ELOQUENT-3 trial, the FDA has approved elotuzumab (Empliciti) in combination with pomalidomide (Pomalyst) and dexamethasone for the treatment of relapsed or refractory multiple myeloma. The trial showed that elotuzumab-treated patients had progression-free survival of 10.3 months compared with 4.7 months for those in the control group of pomalidomide and dexamethasone alone.
Read the full story.
Create a free account.
Sign Up to instantly read 30000+ free Articles & 1000+ Case Studies